### SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

### FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 20, 2003

# INCARA PHARMACEUTICALS CORPORATION

 $(Exact\ name\ of\ registrant\ as\ specified\ in\ its\ charter)$ 

Delaware 0-27410 56-1924222 (State or other (Commission (IRS Employer

jurisdiction of incorporation) File Number) ID Number)

P.O. Box 14287

79 T. W. Alexander Drive

4401 Research Commons, Suite 200

Research Triangle Park, North Carolina

27709

## Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 8-K

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code (919) 558-8688

## Edgar Filing: INCARA PHARMACEUTICALS CORP - Form 8-K

Item 5.	Other Events and Regulation FD Disclosure	
On November 20, 2003, Incara Pharmaceuticals Corporation issued a press release announcing that its stockholders approved its corporate reorganization. A copy of this press release is attached as an exhibit.		
Item 7.	Financial Statements and Exhibits	
(c)	Exhibits	
	Exhibit 99.1 Press release dated November 20, 2003	
SIGNATURE		
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.		
Date: November 20, 2003		INCARA PHARMACEUTICALS CORPORATION
		/s/ Richard W. Reichow
	1	Richard W. Reichow
	1	Executive Vice President and Chief Financial Officer